// App-Quantinova.ai

P1100 : BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)

Researchers

Presenter

  • Toby A. Eyre

Principal Investigators

  • Nirav N. Shah

  • Steven Le Gouill

  • Martin Dreyling

  • Elisabeth Vandenberghe

  • Wojciech Jurczak

  • Yucai Wang

  • Chan Y. Cheah

  • Mitul Gandhi

  • Christopher Chay

  • Jeff P. Sharman

  • David J. Andorsky

  • Ming Yin

  • Minna Balbas

  • Jennifer Kherani

  • Michael L. Wang

Medical Centers

  • Service d’hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France

  • Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR

  • Oxford Uni

  • Messino Cancer Centers ,Asheville,Stati Uniti

  • University of Texas MD Anderson Cancer Center,Houston,Stati Uniti

  • Rocky Mountain Cancer Centers, US Oncology Research ,Eugene,United States

  • Linear Clinical Research and Sir Charles Gairdner Hospital,Perth,Australie

  • Virginia Cancer Specialists, Fairfax, VA, United States

  • Hope Directorate St. James Hospital, Dublin,Irlanda

  • Medical College of Wisconsin, Milwaukee,États-unis

  • Loxo Oncology,Stamford,Verenigde Staten

  • Service d’hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France

  • Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR

  • Messino Cancer Centers ,Asheville,Vereinigte Staaten

  • Hope Directorate St. James Hospital, Dublin,Irlanda

  • Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center,Oxford,United Kingdom

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Loxo Oncology,Stamford,Verenigde Staten

  • Loxo Oncology at Lilly,Stam

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Messino Cancer Centers ,Asheville,Stati Uniti

  • Division of Hematology, Mayo...

  • Rocky Mountain Cancer Centers, US Oncology Research ,Eugene,United States

  • Division of Hematology,Mayo Clinic,Rochester,Verenigde Staten

  • Rocky Mountain Cancer Centers, US Oncology Research ,Eugene,United States

  • Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Australia

  • Loxo Oncology,Stamford,Verenigde Staten

  • Hope Directorate St. James Hospital, Dublin,Irlanda

  • Linear Clinical Research and Sir Charles Gairdner Hospital,Perth,Australie

  • Division of Hematology, Mayo Clinic,Rochester, MN,États-unis

  • Loxo Oncology,Stamford,Verenigde Staten

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Hope Directorate St. James Hospital, Dublin,Irlanda

  • Messino Cancer Centers ,Asheville,Stati Uniti

  • Messino Cancer Centers ,Asheville,Vereinigte Staaten

  • Loxo Oncology at Li

  • Medical College of Wisconsin ,Milwaukee,Vereinigte Staaten

  • Medicine III,LMU University Hospital ,Munich,Alemanha

  • Medicine III,LMU U

  • Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center,Oxford,United Kingdom

  • Medicine III,LMU University Hospital ,Munich,Alemanha

  • Medicine III,LMU University Hospital ,Munich,Alemanha

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Loxo Oncology,Stamford,Verenigde Staten

  • Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR

  • Messino Cancer Centers ,Asheville,Vereinigte Staaten

  • Loxo Oncology at Lilly ,Stamford,Stati Uniti

  • Department of Medicine III, LMU University Hospital,Munich,Deutschland

  • Messino Can

  • Virginia Cancer Specialists, Fairfax, VA, United States

  • Medicine III,LMU University Hospital ,Munich,Alemanha

  • Department of Medicine III, LMU University Hospital,Munich,Deutschland

  • Medical College of WI

  • Division of Epidemiology, Mayo Clinic, Rochester, United States

  • Leukemia,The University of Texas MD Anderson Cancer Center,HOUSTON,Estados Unidos

  • Linear Clinical Res

  • Division of Hematology, Mayo Clinic,Rochester, MN,États-unis

  • Virginia Cancer Specialists, Fairfax, VA

  • Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center,Oxford,United Kingdom

  • Rocky Mountain Cancer Centers, US Oncology Research ,Eugene,Vereinigte Staaten

  • Loxo Oncology at Lilly ,Stamford,Stati Uniti

  • Will

  • Medical College of Wisconsin, Milwaukee,États-unis

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Service d'hématologie clinique du CHU de

  • Medical College of Wisconsin, Milwaukee,États-unis

  • Leukemia,The University of Texas MD Anderson Cancer Center,HOUSTON,Estados Unidos

  • Loxo Oncology,Stamford,Verenigde Staten

  • Department of Medicine III, LMU University Hospital,Munich,Deutschland

  • Hope Directorate St. James Hospital, Dublin,Irlanda

  • Hope Directorate St. James Hospital,

  • Medical College of Wisconsin ,Milwaukee,Vereinigte Staaten

  • Maria Sk

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Rocky Mountain Cancer Centers

  • Division of Hematology,Mayo Clinic,Rochester,Verenigde Staten

  • Rocky Mountain Cancer Centers, US Oncology Research ,Eugene,United States

  • Virginia Cancer Specialists, Fairfax, VA, United States

  • Service d’hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France

  • Division of Hematology, Mayo Clinic,Rochester, MN,États-unis

  • Medical College of Wisconsin, Milwaukee, Wisconsin , United States

  • Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center,Oxford,United Kingdom

  • Loxo Oncology at Lilly ,Stamford,Stati Uniti

  • Loxo Oncology at Lilly ,Stamford,Stati Uniti

  • Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR

Locations

  • United States

  • United Kingdom

  • France

  • Germany

  • Ireland

  • Poland

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Stroke

Biomarkers

  • Bruton tyrosine kinase

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • ACP-196

  • Ibrutinib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Superiority

Phase

  • III

Study Id's

  • NCT04662255

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved